EUVIMEDEUVIMED entdecken
Open Access

Ovarian tissue cryopreservation for fertility preservation before hematopoietic stem cell transplantation in patients with sickle cell disease: safety, ovarian function follow-up, and results of ovarian tissue transplantation

Mitawa Millin Missontsa, Françoise Bernaudin, Anne Fortin, Nathalie Dhédin, Corinne Pondarré, Karima Yakouben, Bénédicte Neven, Martin Castelle, Marina Cavazzana, Harry Lezeau, Matthieu Peycelon, Annabel Paye-Jaouen und 13 weitere

Journal of Assisted Reproduction and Genetics · 2024

DOI: 10.1007/s10815-024-03054-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Assisted Reproduction and Genetics, 2024. Verfasst von Mitawa Millin Missontsa und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Adolescents and Young Adults Unit, Fertility Preservation, APHP, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75010, Pa…. Hauptthemen laut MEDLINE: Fertility Preservation, Hematopoietic Stem Cell Transplantation, Cryopreservation, Anemia, Sickle Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To describe the experience of performing ovarian tissue cryopreservation (OTC) before hematopoietic stem cell transplantation (HSCT), among girls/women with severe sickle cell disease (SCD)(SS or S/β0-thalassemia) who are, besides the usual surgical risk, at risk of SCD-related complications during the fertility preservation procedure for improving their counseling and management. METHODS: This retrospective study included 75 patients (girls/women) with SCD who have had OTC before myeloablative conditioning regimen (MAC) for HSCT. Characteristics of patients and data on OTC, ovarian status follow-up, and results of ovarian tissue transplantation (OTT) were collected in medical records. RESULTS: At OTC, the median (IQR 25-75; range) age of the patients was 9.6 (6.9-14.1; 3.6-28.3) years, 56/75 were prepubertal, and no SCD or surgery-related complications occurred. The median follow-up post-HSCT was > 9 years. At the last follow-up, among prepubertal patients at HSCT, 26/56 were ≥ 15 years old and presented with a premature ovarian insufficiency (POI), except 2, including the patient who had received an OTT to induce puberty. Eight were 13-15 years old and presented for POI. The remaining 22 patients were under 13. Among the 19 patients who were menarche at HSCT, 2 died 6 months post-HSCT and we do not have ovarian function follow-up for the other 2 patients. All the remaining patients (n = 15) had POI. Five patients had OTT. All had a return of ovarian function. One patient gave birth to a healthy baby. CONCLUSION: OTC is a safe fertility preservation technique and could be offered before MAC independent of the patient's age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fertility PreservationHematopoietic Stem Cell TransplantationCryopreservationAnemia, Sickle CellOvaryPrimary Ovarian InsufficiencyHumansFemaleChildAdolescentAdultFollow-Up StudiesYoung AdultChild, PreschoolRetrospective StudiesTransplantation ConditioningPregnancy

Stichwörter der Autor:innen

Fertility preservationHematopoietic stem cell transplantationOvarian function follow-upOvarian tissue cryopreservationOvarian tissue transplantationSickle cell disease

Autor:innen und Institutionen

  • Department of Hematology, Adolescents and Young Adults Unit, Fertility Preservation, APHP, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, 75010, Paris, France.
  • Clinique Ngaliema Fertility Center, 42 Avenue Pumbu, Gombe, Kinshasa, Congo.
  • Pediatric Department Sickle Cell Referral Center, Intercommunal Hospital of Créteil, 94000, Creteil, France.
  • Department of Obstetrics Gynecology, APHP, Pitié-Salpêtrière-Charles Foix University Hospital, 75013, Paris, France.
  • University Paris XII, Inserm U 955, 94000, Creteil, France.
  • Department of Pediatric Immunology and Hematology, APHP, University Paris Cité, Robert Debré Hospital, 75019, Paris, France.

Zitieren

APA

Missontsa, M. M., Bernaudin, F., Fortin, A., Dhédin, N., Pondarré, C., Yakouben, K., Neven, B., Castelle, M., Cavazzana, M., Lezeau, H., Peycelon, M., Paye-Jaouen, A., Sroussi, J., Diesch-Furlanetto, T., Barraud-Lange, V., Sarnacki, S., Fahd, M., Marchand, I., Delcour, C., …, & Poirot, C. (2024). Ovarian tissue cryopreservation for fertility preservation before hematopoietic stem cell transplantation in patients with sickle cell disease: safety, ovarian function follow-up, and results of ovarian tissue transplantation. Journal of Assisted Reproduction and Genetics. https://doi.org/10.1007/s10815-024-03054-4

Vancouver

Missontsa MM, Bernaudin F, Fortin A, Dhédin N, Pondarré C, Yakouben K, et al. Ovarian tissue cryopreservation for fertility preservation before hematopoietic stem cell transplantation in patients with sickle cell disease: safety, ovarian function follow-up, and results of ovarian tissue transplantation. Journal of Assisted Reproduction and Genetics. 2024. doi:10.1007/s10815-024-03054-4

BibTeX
@article{Missontsa2024,
  author = {Missontsa, Mitawa Millin and Bernaudin, Françoise and Fortin, Anne and Dhédin, Nathalie and Pondarré, Corinne and Yakouben, Karima and Neven, Bénédicte and Castelle, Martin and Cavazzana, Marina and Lezeau, Harry and Peycelon, Matthieu and Paye-Jaouen, Annabel and Sroussi, Jeremy and Diesch-Furlanetto, Tamara and Barraud-Lange, Virginie and Sarnacki, Sabine and Fahd, Mony and Marchand, Isis and Delcour, Clémence and Vexiau, Dominique and Arlet, Jean-Benoît and Kamdem, Annie and Arnaud, Cécile and Dalle, Jean-Hugues and Poirot, Catherine},
  title = {Ovarian tissue cryopreservation for fertility preservation before hematopoietic stem cell transplantation in patients with sickle cell disease: safety, ovarian function follow-up, and results of ovarian tissue transplantation},
  journal = {Journal of Assisted Reproduction and Genetics},
  year = {2024},
  doi = {10.1007/s10815-024-03054-4}
}
Kostenlos starten →